Company Filing History:
Years Active: 2013-2015
Title: Innovations of Jonathan Michael Wojciak
Introduction
Jonathan Michael Wojciak is an accomplished inventor based in Encinitas, California. He has made significant contributions to the field of biochemistry, particularly in the development of innovative methods and compositions related to lipid binding and antibody design. With a total of two patents to his name, Wojciak's work has the potential to impact various therapeutic applications.
Latest Patents
Wojciak's latest patents include "Compositions and methods for binding lysophosphatidic acid" and "Antibody design using anti-lipid antibody crystal structures." The first patent describes compositions and methods for creating anti-LPA agents, such as monoclonal antibodies. It discloses variable domain and complementarity determining region amino acid sequences of several monoclonal antibodies against LPA, along with a consensus anti-LPA monoclonal antibody variable domain sequence. The second patent provides methods for designing optimized antibodies, including humanized or human antibodies, aimed at targeting bioactive lipids. These methods can be performed in silico and are intended to enhance the binding affinity of antibodies to their original target lipids.
Career Highlights
Wojciak is currently associated with Lpath, Inc., a company focused on developing innovative therapeutic solutions. His work at Lpath has allowed him to explore the intersection of lipid biology and antibody technology, leading to advancements in the treatment of various diseases.
Collaborations
Throughout his career, Wojciak has collaborated with notable colleagues, including Roger A. Sabbadini and William A. Garland. These collaborations have contributed to the advancement of research in the field of lipid-binding antibodies.
Conclusion
Jonathan Michael Wojciak is a notable inventor whose work in lipid binding and antibody design has the potential to revolutionize therapeutic approaches. His contributions through patents and collaborations highlight his commitment to innovation in biochemistry.